And speaking of royalties 85,586,795 Todos shar
Post# of 30027
(Total Views: 373)
Posted On: 04/01/2022 6:16:20 AM
And speaking of royalties
85,586,795 Todos shares owned by AMARANTUS ,
In addition a 10% royalty on LymPro intellectual property.
(LymPro Test™has been valued at $136 million by an independent third-party valuation firm...)
On July 28, 2020, Todos Medical Ltd. (the “Company”) entered into Amendment No. 1 to the Binding Joint Venture Agreement with Amarantus Bioscience Holdings, Inc. (“Amarantus”) pursuant to which the parties agreed that the Company would issue 49.9% of its ordinary shares as of December 31, 2019 to Amarantus in exchange for the
80.1% equity interest it does not own of Breakthrough Diagnostics, Inc. In addition, Amarantus will receive a 10% royalty on LymPro intellectual property.
https://investor.todosmedical.com/sec-filings...0-014099-1
In addition, we have the second half of an ongoing clinical trial for our LymPro Alzheimer’s blood test at the University of Leipzig in Germany that we expect to readout in the first half of 2022. As a reminder, this clinical study is evaluating the correlation between LymPro scores and amyloid concentrations in the brain as measured by SUVR, and the first half of the study showed a strong statistical significance of the correlation with p = 0.00000216 and r = 0.85. We are very hopeful that LymPro, a dynamic functional assay that measures immune response in the blood that mimics ongoing pathology in the brain, will become an important tool to qualify patients who are most likely to benefit from amyloid treatment. LymPro measures the fundamental underlying biology of Alzheimer’s disease that we believe can be identified at the pre-symptomatic phase given that key LymPro markers appear to be stage-independent even at the mild cognitive impairment (MCI) stage.
https://investorshangout.com/post/view?id=6314972
85,586,795 Todos shares owned by AMARANTUS ,
In addition a 10% royalty on LymPro intellectual property.
(LymPro Test™has been valued at $136 million by an independent third-party valuation firm...)
On July 28, 2020, Todos Medical Ltd. (the “Company”) entered into Amendment No. 1 to the Binding Joint Venture Agreement with Amarantus Bioscience Holdings, Inc. (“Amarantus”) pursuant to which the parties agreed that the Company would issue 49.9% of its ordinary shares as of December 31, 2019 to Amarantus in exchange for the
80.1% equity interest it does not own of Breakthrough Diagnostics, Inc. In addition, Amarantus will receive a 10% royalty on LymPro intellectual property.
https://investor.todosmedical.com/sec-filings...0-014099-1
In addition, we have the second half of an ongoing clinical trial for our LymPro Alzheimer’s blood test at the University of Leipzig in Germany that we expect to readout in the first half of 2022. As a reminder, this clinical study is evaluating the correlation between LymPro scores and amyloid concentrations in the brain as measured by SUVR, and the first half of the study showed a strong statistical significance of the correlation with p = 0.00000216 and r = 0.85. We are very hopeful that LymPro, a dynamic functional assay that measures immune response in the blood that mimics ongoing pathology in the brain, will become an important tool to qualify patients who are most likely to benefit from amyloid treatment. LymPro measures the fundamental underlying biology of Alzheimer’s disease that we believe can be identified at the pre-symptomatic phase given that key LymPro markers appear to be stage-independent even at the mild cognitive impairment (MCI) stage.
https://investorshangout.com/post/view?id=6314972
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼